疟疾疫苗在临床试验中显示出87%的有效率
Malaria vaccine shows 87% efficacy in clinical trial
一项针对疟疾疫苗PfSPZ-LARC2的临床试验显示,87%的受试者在接种疫苗后未感染疟疾。该疫苗在西非菌株和巴西菌株挑战下表现出跨菌株保护效果。研究结果在华盛顿特区的美国热带医学和卫生学会年会上公布。
展示了疟疾疫苗在预防感染方面的高效率,为全球疟疾防控提供了重要进展。
The novel, genetically attenuated whole-parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.
Among 22 participants exposed to a controlled malaria challenge 12 to 16 weeks after their last dose of the vaccine, all seven placebo recipients became infected, while only two of 15 vaccinated individuals developed an infection. All infected participants were safely and promptly treated. In addition, the vaccine was safe and well tolerated in the vaccinated participants.
These findings were presented today at the annual meeting of the American Society of Tropical Medicine and Hygiene in Washington, D.C. They were reported by Dr. Sean C. Murphy, professor of laboratory medicine and pathology at the University of Washington School of Medicine and medical director of the Department of Laboratories at Seattle Children's Hospital.
The recently completed trial was conducted by UW Medicine and its partners as part of the Infectious Diseases Clinical Research Consortium, or IDCRC.
The trial began enrollment in the summer of 2025. The study's co-principal investigators, along with Murphy, are Dr. Jim Kublin of the Fred Hutch Cancer Center's Vaccine and Infectious Disease Division and Dr. R. Scott McClelland, professor of medicine, epidemiology and global health at UW School of Medicine, who led clinical site operations at Harborview Medical Center's Virology Research Clinic.
Because there are over 600,000 deaths worldwide each year from malaria, vaccines that completely block infection—rather than just reduce symptom severity—are urgently needed.
The attenuated PfLARC2 strain was created in Dr. Stefan Kappe's laboratory at Seattle Children's. Kappe is now director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine in Baltimore. Co-inventors also include former lab member Dr. Debashree Goswami and Dr. Ashley Vaughan at Seattle Children's. The strain was further developed, manufactured and advanced to the clinical stage by Sanaria Inc.
"We engineered the PfLARC2 strain with the goal to have a safe vaccine that stimulates a superior response against malaria parasite infection in the liver. It is truly rewarding to see that this vaccine is safe and how well it has protected against challenge with a highly divergent malaria strain in the Seattle trial," Kappe said.
This live-attenuated vaccine exposes the human immune system to a wide assortment of parasite proteins. The parasite grows like a normal malaria parasite until two genetic deletions in the vaccine safely halt the parasite's growth during its liver stage.
"This study was made possible by the culmination of decades' worth of research on the biology of Plasmodium parasites and the maturation of genetic engineering technologies that allowed scientists to modify the parasite genome to make it safe for use in humans and yet tuned just right to induce strong protective immune responses," Murphy said.
The study's "challenge" design meant that the vaccine's efficacy was tested by deliberately exposing vaccinated and placebo-treated participants to live malaria parasites under carefully controlled conditions. This study's test of efficacy was notable because of the long gap between immunization and challenge (12 to 16 weeks) and the use of a variant malaria strain in the challenge itself. This required the PfSPZ-LARC2 Vaccine to achieve durable, cross-strain immunity to provide protection.
The ability to protect across variant strains is important since the P. falciparum parasite is geographically diverse, and it is important for the vaccine to be protective everywhere that malaria is transmitted. In this trial, the vaccine strain used is from West Africa, and the challenge strain is from Brazil.
"It takes a strong and well-coordinated clinical trial team with excellent laboratory resources and with highly engaged and committed research participants to carry out these kinds of studies," McClelland said.
Kublin noted that Seattle has a unique testing facility for participants and an altruistic study population that make human challenge studies possible. "Our teams at UW Medicine and Fred Hutch have been conducting malaria human challenge studies since 2011 and have used the model to provide important insights about new drugs and vaccines," Kublin said.
Highly sensitive assaying for these studies is provided by the UW Medicine Malaria Molecular Diagnostic Laboratory, which Murphy directs.
"We look forward to continuing to advance this vaccine and other promising products that can combat malaria using our unique clinical trial resources here in Seattle," Murphy said.
Key medical concepts
Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Malaria vaccine shows 87% efficacy in clinical trial (2026, November 20) retrieved 20 November 2026 from https://medicalxpress.com/news/2026-11-malaria-vaccine-efficacy-clinical-trial.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com